Skip to main content

Table 1 Demographic and clinical characteristics upon initial admission between MG patients with and without recurrent infection

From: Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study

 

Total

Non-recurrent

Recurrent

P-value

Number of patients

272/272 (100%)

176/272 (64.7%)

96/272 (35.3%)

NA

Male

115/272 (42.3%)

72/176 (40.9%)

43/96 (44.8%)

0.536

Age, year

53.0 (39.3–67.9)

52.0 (35.3–66.0)

58.5 (44.0–71.0)

0.024*

Respiratory and bulbar function

 V5

232/272 (85.3%)

159/176 (90.3%)

73/96 (76.0%)

0.001**

 VE

27/272 (9.9%)

10/176 (5.7%)

17/96 (17.7%)

0.002**

Motor scale (MRC)

 Bilateral deltoid and iliopsoas

20.0 (16.0–20.0)

20.0 (18.0–20.0)

19.5 (16.0–20.0)

0.003**

Concomitant diseases

 Diabetes mellitus

49/272 (14.7%)

18/176 (10.2%)

22/96 (22.9%)

0.005**

 Deep vein thrombosis

6/272 (2.2%)

1/176 (0.6%)

5/96 (5.2%)

0.022a*

 Thymic cancer

47/272 (17.3%)

23/176 (13.1%)

24/96 (25.0%)

0.013*

Duration of hospitalization, day

15.0 (9.0–23.0)

14.0 (8.0–21.0)

16.5 (12.0–28.0)

0.004**

Foley catheterization

96/272 (35.3%)

69/176 (39.2%)

27/96 (28.1%)

0.068

Ventilator dependency

74/272 (27.2%)

51/176 (29.0%)

23/96 (24.0%)

0.374

Plasmapheresis

58/272 (21.3%)

31/176 (17.6%)

27/96 (28.1%)

0.043*

Seropositivity of AChR antibody

215/272 (79.0%)

133/176 (75.6%)

82/96 (85.4%)

0.056

Laboratory data

 Hb, g/dL

13.3 (12.2–14.6)

13.6 (12.4–14.9)

13.1 (11.6–14.1)

0.051

 Creatinine, mg/dL

0.8 (0.6–1.0)

0.7 (0.6–0.9)

0.8 (0.7–1.0)

0.014*

 K, mEq/L

3.9 (3.5–4.2)

3.9 (3.6–4.2)

3.8 (3.5–4.1)

0.021*

 Mg, mEq/L

1.8 (1.6–1.9)

1.8 (1.6–2.0)

1.7 (1.5–1.9)

0.032b*

 Albumin, g/dL

4.0 (3.3–4.4)

4.1 (3.4–4.4)

3.9 (3.2–4.3)

0.037*

 APTT, sec

26.5 (23.9–29.2)

26.5 (23.9–28.6)

26.5 (24.3–31.1)

0.158

 Cortisol, μg/dL

12.8 (5.4–18.0)

14.0 (8.9–18.5)

9.9 (3.2–17.6)

0.079

Pneumonia

49/272 (18.0%)

25/176 (14.2%)

24/96 (25.0%)

0.027*

UTI

25/272 (9.2%)

11/176 (6.3%)

14/96 (14.6%)

0.023*

Bacteremia

17/272 (6.3%)

11/176 (6.3%)

6/96 (6.3%)

1.000

Multiple infections

18/272 (6.6%)

10/176 (5.7%)

8/96 (8.3%)

0.401

  1. AChR acetylcholine receptor, APTT activated partial thromboplastin time, GCS Glasgow coma scale, Hb hemoglobin, K potassium, MG myasthenia gravis, Mg magnesium, MRC Medical Research Council scale, NA not applicable, UTI urinary tract infection, V5 oriented to verbal response of GCS and no significant respiratory distress and bulbar impairment, VE difficulty in evaluating GCS due to endotracheal intubation indicating severe bulbar impairment or respiratory distress. A p-value below 0.05 was considered statistically significant. *p < 0.05; **p < 0.01; aFisher’s exact test; bTwo-Sample t test. Unless otherwise reported, qualitative values were expressed as percentage (n/total, %), quantitative values were median (interquartile range IQR)
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us